Company / Revenue
Avalo Therapeutics, Inc. Revenue History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Revenue
$59.0K
FY2025
5-year range
$59.0K / $18.1M
FY2021-FY2025
Trend
-86.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Revenue has declined for 3 consecutive years, from $18M in FY2022 to $59,000 in FY2025.
Based on SEC 10-K filings.
$59,000 in FY2025 with a 5-year CAGR of -61.2%.
Declined from $2M to $59,000 over the past 2 years.
Revenue over time
Growth rates
- 3-Year CAGR
- -85.2%
- 5-Year CAGR
- -61.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- Avalo Therapeutics, Inc.'s revenue has declined for 3 consecutive years.
- 5-year CAGR of -61.2%, indicating a declining trend.
- In FY2025, revenue decreased 86.6% year-over-year.
- Peak revenue was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.59 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $59.0K | -86.6% |
| FY2024 | $441.0K | -77.1% |
| FY2023 | $1.9M | -89.3% |
| FY2022 | $18.1M | +234.4% |
| FY2021 | $5.4M | -19.4% |
| FY2020 | $6.7M | -0.8% |
| FY2019 | $6.8M | -4.0% |
| FY2018 | $7.0M | -74.7% |
| FY2017 | $27.8M | - |
As of FY2025 · SEC Form 10-K · Last checked Jun 21, 2026